Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 1991;28(2):130-4.
doi: 10.1007/BF00689702.

Pharmacokinetics of high-dose busulphan in relation to age and chronopharmacology

Affiliations

Pharmacokinetics of high-dose busulphan in relation to age and chronopharmacology

M Hassan et al. Cancer Chemother Pharmacol. 1991.

Abstract

Busulphan levels in plasma were measured in 27 patients during conditioning therapy (1 mg/kg x 4 for 4 days) before bone marrow transplantation. The mean minimal concentration found in children aged less than 5 years (237 ng ml-1) was lower than that observed in adults or older children (607 and 573 ng ml-1, respectively). The AUC for the last dose was significantly lower in young children (2.315 h ng ml-1) than in adults or older children (6,134 and 5,937 h ng ml-1, respectively). The elimination half-life for the last dose in young children was shorter (2.05 h) than that in either adults (2.59 h) or older children (2.79 h). When the AUC was normalized for body surface area, the difference between young children and the other groups was smaller but remained statistically significant. The total body clearance was significantly higher in young children (7.3 ml min-1 kg-1) as compared with both older children and adults (3.02 and 2.7 ml min-1 kg-1, respectively). The plasma levels of busulphan showed circadian rhythmicity, especially in young children. The concentration measured during the night in some patients was up to 3-fold that observed during daytime. We conclude that the busulphan dosage for children must be reconsidered and that further studies are urgently needed to develop an optimal therapy.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Drugs. 1989 Feb;37(2):113-5 - PubMed
    1. J Chromatogr. 1983 Oct 14;277:374-80 - PubMed
    1. Clin Biochem. 1985 Jun;18(3):154-7 - PubMed
    1. Clin Pharmacokinet. 1987 Mar;12(3):168-213 - PubMed
    1. Clin Pharmacokinet. 1989 Jun;16(6):327-36 - PubMed

Publication types

LinkOut - more resources